Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | MLYCD | O95822 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | ESRRG | P62508 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16808347 | 0.91 | MAPT (0.59) | MAPTL3MBTL1HTTSYKSMN1; SMN2 | |
| SCHEMBL31471684 | 0.88 | MAPT (0.56) | MAPTL3MBTL1HTTSYKSMN1; SMN2 | |
| SCHEMBL938685 | 0.87 | MAPT (0.53) | MAPTL3MBTL1HTTSYKSMN1; SMN2 | |
| SCHEMBL13480435 | 0.86 | MAPT (0.65) | MAPTL3MBTL1HTTSYKSMN1; SMN2 | |
| SCHEMBL15092810 | 0.85 | MAPT (0.64) | MAPTL3MBTL1HTTSYKSMN1; SMN2 | |
| SCHEMBL13090607 | 0.85 | MAPT (0.64) | MAPTL3MBTL1HTTSYKSMN1; SMN2 | |
| SCHEMBL15679441 | 0.85 | MAPT (0.64) | MAPTL3MBTL1HTTSYKSMN1; SMN2 | |
| SCHEMBL20385193 | 0.85 | MAPT (0.64) | MAPTL3MBTL1HTTSYKSMN1; SMN2 | |
| SCHEMBL30605344 | 0.85 | SIGMAR1 (0.51) | MAPTL3MBTL1HTTSYKSIGMAR1 | |
| SCHEMBL2325792 | 0.84 | MAPT (0.65) | MAPTL3MBTL1HTTSYKSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875619-B2 | N-[4-(4-{2-[bis-((2S,3R)-2,3,4-trihydroxybutyl)amino]ethylamino}phenyl)butyl]-N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidine trihydrochloride; treating chronic bronchitis, cystic fibrosis, ventilator-induced pneumonia, asthma, chronic obstructive pulmonary disease, pneumonia and emphysema | PARION SCIENCES, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20060142581-A1 | Hetero substitued sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142581-A1 | Hetero substitued sodium channel blockers | SCN2B, CACNA1B, CACNA1G | HSP90AA1 3199/4885MLYCD 2455/4885MAPT 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.